Cargando…

Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial

SIMPLE SUMMARY: Gastroesophageal adenocarcinoma (GOA) is a cancer that has poor survival. Most cases are diagnosed when a cure is not possible, and treatment often has many side effects. It occurs less often and is associated with better outcomes in females. The reason for this is not known. We soug...

Descripción completa

Detalles Bibliográficos
Autores principales: Baxter, Mark A., Spender, Lindsay C., Walsh, Shaun, Bray, Susan, Skinner, Gemma, King, Sharon, Hall, Peter S., Seymour, Matthew J., Petty, Russell D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177024/
https://www.ncbi.nlm.nih.gov/pubmed/37174057
http://dx.doi.org/10.3390/cancers15092591
_version_ 1785040540108062720
author Baxter, Mark A.
Spender, Lindsay C.
Walsh, Shaun
Bray, Susan
Skinner, Gemma
King, Sharon
Hall, Peter S.
Seymour, Matthew J.
Petty, Russell D.
author_facet Baxter, Mark A.
Spender, Lindsay C.
Walsh, Shaun
Bray, Susan
Skinner, Gemma
King, Sharon
Hall, Peter S.
Seymour, Matthew J.
Petty, Russell D.
author_sort Baxter, Mark A.
collection PubMed
description SIMPLE SUMMARY: Gastroesophageal adenocarcinoma (GOA) is a cancer that has poor survival. Most cases are diagnosed when a cure is not possible, and treatment often has many side effects. It occurs less often and is associated with better outcomes in females. The reason for this is not known. We sought to use samples from a clinical trial in older adults with GOA to investigate whether this observation could be related to oestrogen and its action through oestrogen receptors. We found no clear link between outcome and oestrogen receptor expression but did note improved survival with older age and female sex. ABSTRACT: Gastroesophageal adenocarcinoma is a disease of older adults that is associated with a very poor prognosis. It is less common and has better outcomes in females. The reason for this is unknown but may relate to signalling via the main oestrogen receptors (ER) α and β. In this study, we sought to investigate this using the GO2 clinical trial patient cohort. GO2 recruited older and/or frail patients with advanced gastroesophageal cancer. Immunohistochemistry was performed on tumour samples from 194 patients. The median age of the population was 76 years (range 52–90), and 25.3% were female. Only one (0.5%) tumour sample was positive for ERα, compared to 70.6% for ERβ expression. There was no survival impact according to ERβ expression level. Female sex and younger age were associated with lower ERβ expression. Female sex was also associated with improved overall survival. To our knowledge, this is the largest study worldwide of ER expression in a cohort of patients with advanced gastroesophageal adenocarcinoma. It is also unique, given the age of the population. We have demonstrated that female sex is associated with better survival outcomes with palliative chemotherapy but that this does not appear to be related to ER IHC expression. The differing ER expression according to age supports the concept of a different disease biology with age.
format Online
Article
Text
id pubmed-10177024
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101770242023-05-13 Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial Baxter, Mark A. Spender, Lindsay C. Walsh, Shaun Bray, Susan Skinner, Gemma King, Sharon Hall, Peter S. Seymour, Matthew J. Petty, Russell D. Cancers (Basel) Article SIMPLE SUMMARY: Gastroesophageal adenocarcinoma (GOA) is a cancer that has poor survival. Most cases are diagnosed when a cure is not possible, and treatment often has many side effects. It occurs less often and is associated with better outcomes in females. The reason for this is not known. We sought to use samples from a clinical trial in older adults with GOA to investigate whether this observation could be related to oestrogen and its action through oestrogen receptors. We found no clear link between outcome and oestrogen receptor expression but did note improved survival with older age and female sex. ABSTRACT: Gastroesophageal adenocarcinoma is a disease of older adults that is associated with a very poor prognosis. It is less common and has better outcomes in females. The reason for this is unknown but may relate to signalling via the main oestrogen receptors (ER) α and β. In this study, we sought to investigate this using the GO2 clinical trial patient cohort. GO2 recruited older and/or frail patients with advanced gastroesophageal cancer. Immunohistochemistry was performed on tumour samples from 194 patients. The median age of the population was 76 years (range 52–90), and 25.3% were female. Only one (0.5%) tumour sample was positive for ERα, compared to 70.6% for ERβ expression. There was no survival impact according to ERβ expression level. Female sex and younger age were associated with lower ERβ expression. Female sex was also associated with improved overall survival. To our knowledge, this is the largest study worldwide of ER expression in a cohort of patients with advanced gastroesophageal adenocarcinoma. It is also unique, given the age of the population. We have demonstrated that female sex is associated with better survival outcomes with palliative chemotherapy but that this does not appear to be related to ER IHC expression. The differing ER expression according to age supports the concept of a different disease biology with age. MDPI 2023-05-03 /pmc/articles/PMC10177024/ /pubmed/37174057 http://dx.doi.org/10.3390/cancers15092591 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Baxter, Mark A.
Spender, Lindsay C.
Walsh, Shaun
Bray, Susan
Skinner, Gemma
King, Sharon
Hall, Peter S.
Seymour, Matthew J.
Petty, Russell D.
Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial
title Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial
title_full Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial
title_fullStr Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial
title_full_unstemmed Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial
title_short Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial
title_sort female sex but not oestrogen receptor expression predicts survival in advanced gastroesophageal adenocarcinoma—a post-hoc analysis of the go2 trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177024/
https://www.ncbi.nlm.nih.gov/pubmed/37174057
http://dx.doi.org/10.3390/cancers15092591
work_keys_str_mv AT baxtermarka femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial
AT spenderlindsayc femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial
AT walshshaun femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial
AT braysusan femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial
AT skinnergemma femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial
AT kingsharon femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial
AT hallpeters femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial
AT seymourmatthewj femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial
AT pettyrusselld femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial
AT femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial